RT Journal Article
SR Electronic
T1 Preoperative Intensification Treatment in Patients with Rectal Adenocarcinoma – A Standardization of Clinical Practice
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.01.09.23284351
DO 10.1101/2023.01.09.23284351
A1 Leal-Costa, Luísa
A1 Silva, Diana
A1 Baptista, Carlota
A1 Bizarro, Rita
A1 Machete, Madalena
A1 Simões, Pedro
A1 Faria, Ana
A1 Teixeira, José Alberto
YR 2023
UL http://medrxiv.org/content/early/2023/01/09/2023.01.09.23284351.abstract
AB Neoadjuvant radiotherapy with concurrent fluoropyrimidines followed by surgery is considered the standard-of-care in locally advanced rectal cancer (LARC). Neoadjuvant chemo-radiotherapy (CRT) is associated with a pathological complete response (pCR) rate of 11-18%. Intensification of neoadjuvant treatment can lead to higher rates of tumor resectability and pCR, although the best therapeutic sequence is unknown.This is a prospective, single arm study which aims to standardize institutional clinical practice in accordance with international recommendations. Patients with LARC received neoadjuvant intensive treatment with concurrent CRT followed by 12 weeks of consolidation chemotherapy (ChT) with CAPOX or mFOLFOX6. Clinical response was accessed by magnetic resonance imaging (MRI) at 10 weeks, 14 weeks, and 18 weeks. If complete clinical response (cCR) was obtained, a watch-and-wait (W&W) strategy was offered; otherwise, surgery was performed. The primary endpoint was to evaluate clinical response rate after 10 weeks of intensification treatment, and its comparison with historical data. Key secondary endpoints included clinical response rate at 14 and 18 weeks, rate of patients who enter W&W strategy, rate of pCR in patients who undergo surgery, recurrence free survival (RFS), overall survival (OS), and rate of adverse effects. We present efficacy and safety preliminary results one year from the start of the study.Six patients with LARC were included. Three had a tumour in the low-rectum, two in middle-rectum and one in high-rectum. At initial magnetic resonance imaging (MRI), two had cT2, three had cT3 and one had cT4; three had cN1 and one cN2; two patients had extramural venous invasion (EMVI+) and one had mesorectal fascia involvement (MRF+).After CRT, all patients started consolidation ChT. The most common grade ≥3 AEs were neutropenia, nausea, and diarrhoea. There were no dose-limiting toxicities and all patients completed treatment. MRI at 10 weeks showed a tumour regression grade (TRG) 2 in three patients, TRG3 in two patients and TRG4 in one patient. Two patients are in the W&W surveillance protocol; one is awaiting MRI at 18 weeks; another patient awaits surgery; and of the two patients already underwent surgery, one had a ypT3N1 and the other had complete pathological response (pCR). To this date there are no recurrence or death events.These preliminary results suggests tolerability and feasibility of a neoadjuvant intensification treatment in patients with LARC.Categories rectal adenocarcinoma, oncologyCompeting Interest StatementThe authors have declared no competing interest.Funding StatementThe author(s) received no specific funding for this work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol was approved by the Hospital Beatriz Ângelo Ethics Committee (ref. CES/580_338). Written informed consent was obtained from all participants in this study.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are stored as de-identified participant data, which are available upon reasonable request from Luísa Leal-Costa (maria.leal.costa{at}hbeatrizangelo.pt).